|
1.Rick, F.G., et al., LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia. Prostate, 2011. 71(7): p. 736-47.
2.Mazzucchelli, R., et al., Prostate changes related to therapy: with special reference to hormone therapy. Future Oncol, 2014. 10(11): p. 1873-86.
3.Miyazawa, Y., et al., Clinical endocrinological evaluation of the gonadal axis (testosterone, LH and FSH) in prostate cancer patients switched from a GnRH antagonist to a LHRH agonist. Basic Clin Androl, 2015. 25: p. 7.
4.Azoulay, L., et al., 5alpha-Reductase Inhibitors and the Risk of Cancer-Related Mortality in Men With Prostate Cancer. JAMA Oncol, 2015. 1(3): p. 314-20.
5.Tan, M.H., et al., Androgen receptor: structure, role in prostate cancer and drug discovery. Acta Pharmacol Sin, 2015. 36(1): p. 3-23.
6.Siegel, R.L., K.D. Miller, and A. Jemal, Cancer statistics, 2016. CA Cancer J Clin, 2016. 66(1): p. 7-30.
7.Siegel, R.L., K.D. Miller, and A. Jemal, Cancer Statistics, 2017. CA Cancer J Clin, 2017. 67(1): p. 7-30.
8.台灣衛生福利部統計資料, http://dep.mohw.gov.tw/DOS/lp-1777-113.html.
9.Thompson, I., et al., Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol, 2007. 177(6): p. 2106-31.
10.Hayden, A.J., C. Catton, and T. Pickles, Radiation therapy in prostate cancer: a risk-adapted strategy. Curr Oncol, 2010. 17 Suppl 2: p. S18-24.
11.Perlmutter, M.A. and H. Lepor, Androgen deprivation therapy in the treatment of advanced prostate cancer. Rev Urol, 2007. 9 Suppl 1: p. S3-8.
12.Antonarakis, E.S., Management of Metastatic Castration-resistant Prostate Cancer. Eur Oncol Haematol, 2011. 07(04): p. 251.
13.Karantanos, T., P.G. Corn, and T.C. Thompson, Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene, 2013. 32(49): p. 5501-11.
14.Yatani, R., et al., Geographic pathology of latent prostatic carcinoma. Int J Cancer, 1982. 29(6): p. 611-6.
15.Gann, P.H., Risk factors for prostate cancer. Rev Urol, 2002. 4 Suppl 5: p. S3-s10.
16.Tavtigian, S.V., et al., A candidate prostate cancer susceptibility gene at chromosome 17p. Nat Genet, 2001. 27(2): p. 172-80.
17.Kolonel, L.N., Fat, meat, and prostate cancer. Epidemiol Rev, 2001. 23(1): p. 72-81.
18.Gann, P.H., et al., A prospective study of plasma hormone levels, nonhormonal factors, and development of benign prostatic hyperplasia. Prostate, 1995. 26(1): p. 40-9.
19.Pollak, M., Insulin-like growth factors and prostate cancer. Epidemiol Rev, 2001. 23(1): p. 59-66.
20.Heinonen, O.P., et al., Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst, 1998. 90(6): p. 440-6.
21.Clark, L.C., et al., Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA, 1996. 276(24): p. 1957-63.
22.Bubendorf, L., et al., Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res, 1999. 59(4): p. 803-6.
23.Sharma, A., et al., The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. J Clin Invest, 2010. 120(12): p. 4478-92.
24.Edwards, J., et al., Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer, 2003. 89(3): p. 552-6.
25.Mao, X., et al., Distinct genomic alterations in prostate cancers in Chinese and Western populations suggest alternative pathways of prostate carcinogenesis. Cancer Res, 2010. 70(13): p. 5207-12.
26.Zhao, X.Y., et al., Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med, 2000. 6(6): p. 703-6.
27.Culig, Z., et al., Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol, 1993. 7(12): p. 1541-50.
28.Guo, Z., et al., Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell, 2006. 10(4): p. 309-19.
29.Holzbeierlein, J., et al., Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol, 2004. 164(1): p. 217-27.
30.Gurel, B., et al., Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod Pathol, 2008. 21(9): p. 1156-67.
31.Nupponen, N.N., et al., Genetic alterations in hormone-refractory recurrent prostate carcinomas. Am J Pathol, 1998. 153(1): p. 141-8.
32.Courtney, K.D., R.B. Corcoran, and J.A. Engelman, The PI3K pathway as drug target in human cancer. J Clin Oncol, 2010. 28(6): p. 1075-83.
33.Taylor, B.S., et al., Integrative genomic profiling of human prostate cancer. Cancer Cell, 2010. 18(1): p. 11-22.
34.Heidegger, I., et al., Diverse functions of IGF/insulin signaling in malignant and noncancerous prostate cells: proliferation in cancer cells and differentiation in noncancerous cells. Endocrinology, 2012. 153(10): p. 4633-43.
35.Nickerson, T., et al., In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). Cancer Res, 2001. 61(16): p. 6276-80.
36.Pandini, G., et al., Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells. Cancer Res, 2005. 65(5): p. 1849-57.
37.McGrogan, B.T., et al., Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta, 2008. 1785(2): p. 96-132.
38.Terry, S., et al., Increased expression of class III beta-tubulin in castration-resistant human prostate cancer. Br J Cancer, 2009. 101(6): p. 951-6.
39.Ploussard, G., et al., Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy. Cancer Res, 2010. 70(22): p. 9253-64.
40.Locher, K.P., Review. Structure and mechanism of ATP-binding cassette transporters. Philos Trans R Soc Lond B Biol Sci, 2009. 364(1514): p. 239-45.
41.Magadoux, L., et al., Emerging targets to monitor and overcome docetaxel resistance in castration resistant prostate cancer (review). Int J Oncol, 2014. 45(3): p. 919-28.
42.O''Neill, A.J., et al., Characterisation and manipulation of docetaxel resistant prostate cancer cell lines. Mol Cancer, 2011. 10: p. 126.
43.Bieging, K.T. and L.D. Attardi, Deconstructing p53 transcriptional networks in tumor suppression. Trends Cell Biol, 2012. 22(2): p. 97-106.
44.Heidenberg, H.B., et al., The role of the p53 tumor suppressor gene in prostate cancer: a possible biomarker? Urology, 1996. 48(6): p. 971-9.
45.Gan, L., et al., Resistance to docetaxel-induced apoptosis in prostate cancer cells by p38/p53/p21 signaling. Prostate, 2011. 71(11): p. 1158-66.
46.Lebedeva, I., et al., Bcl-xL in prostate cancer cells: effects of overexpression and down-regulation on chemosensitivity. Cancer Res, 2000. 60(21): p. 6052-60.
47.Patterson, S.G., et al., Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells. Oncogene, 2006. 25(45): p. 6113-22.
48.Domingo-Domenech, J., et al., Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity. Clin Cancer Res, 2006. 12(18): p. 5578-86.
49.Michalaki, V., et al., Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer, 2004. 90(12): p. 2312-6.
50.Singh, R.K. and B.L. Lokeshwar, Depletion of intrinsic expression of Interleukin-8 in prostate cancer cells causes cell cycle arrest, spontaneous apoptosis and increases the efficacy of chemotherapeutic drugs. Mol Cancer, 2009. 8: p. 57.
51.Warburg, O., On the origin of cancer cells. Science, 1956. 123(3191): p. 309-14.
52.Xu, X.D., et al., Warburg effect or reverse Warburg effect? A review of cancer metabolism. Oncol Res Treat, 2015. 38(3): p. 117-22.
53.Gatenby, R.A. and R.J. Gillies, Why do cancers have high aerobic glycolysis? Nat Rev Cancer, 2004. 4(11): p. 891-9.
54.Parsons, D.W., et al., An integrated genomic analysis of human glioblastoma multiforme. Science, 2008. 321(5897): p. 1807-12.
55.Brand, K.A. and U. Hermfisse, Aerobic glycolysis by proliferating cells: a protective strategy against reactive oxygen species. FASEB J, 1997. 11(5): p. 388-95.
56.Semenza, G.L., Hypoxia-inducible factors in physiology and medicine. Cell, 2012. 148(3): p. 399-408.
57.Baysal, B.E., et al., Prevalence of SDHB, SDHC, and SDHD germline mutations in clinic patients with head and neck paragangliomas. J Med Genet, 2002. 39(3): p. 178-83.
58.Isaacs, J.S., et al., HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell, 2005. 8(2): p. 143-53.
59.Goda, N. and M. Kanai, Hypoxia-inducible factors and their roles in energy metabolism. Int J Hematol, 2012. 95(5): p. 457-63.
60.Bayley, J.P. and P. Devilee, Warburg tumours and the mechanisms of mitochondrial tumour suppressor genes. Barking up the right tree? Curr Opin Genet Dev, 2010. 20(3): p. 324-9.
61.Gordan, J.D., C.B. Thompson, and M.C. Simon, HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation. Cancer Cell, 2007. 12(2): p. 108-13.
62.Okar, D.A., et al., PFK-2/FBPase-2: maker and breaker of the essential biofactor fructose-2,6-bisphosphate. Trends Biochem Sci, 2001. 26(1): p. 30-5.
63.Shim, H., et al., c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc Natl Acad Sci U S A, 1997. 94(13): p. 6658-63.
64.Tran, Q., et al., Targeting cancer metabolism - revisiting the warburg effects. Toxicol Res, 2016. 32(3): p. 177-93.
65.Minchenko, O., I. Opentanova, and J. Caro, Hypoxic regulation of the 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase gene family (PFKFB-1-4) expression in vivo. FEBS Letters, 2003. 554(3): p. 264-270.
66.Acker, T. and K.H. Plate, A role for hypoxia and hypoxia-inducible transcription factors in tumor physiology. J Mol Med (Berl), 2002. 80(9): p. 562-75.
67.Beckert, S., et al., Lactate stimulates endothelial cell migration. Wound Repair Regen, 2006. 14(3): p. 321-4.
68.Vegran, F., et al., Lactate influx through the endothelial cell monocarboxylate transporter MCT1 supports an NF-kappaB/IL-8 pathway that drives tumor angiogenesis. Cancer Res, 2011. 71(7): p. 2550-60.
69.Hardie, D.G., F.A. Ross, and S.A. Hawley, AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol, 2012. 13(4): p. 251-62.
70.Park, H.U., et al., AMP-activated protein kinase promotes human prostate cancer cell growth and survival. Mol Cancer Ther, 2009. 8(4): p. 733-41.
71.Frigo, D.E., et al., CaM kinase kinase beta-mediated activation of the growth regulatory kinase AMPK is required for androgen-dependent migration of prostate cancer cells. Cancer Res, 2011. 71(2): p. 528-37.
72.Karacosta, L.G., et al., A regulatory feedback loop between Ca2+/calmodulin-dependent protein kinase kinase 2 (CaMKK2) and the androgen receptor in prostate cancer progression. J Biol Chem, 2012. 287(29): p. 24832-43.
73.Fu, H., et al., MicroRNA-224 and its target CAMKK2 synergistically influence tumor progression and patient prognosis in prostate cancer. Tumour Biol, 2015. 36(3): p. 1983-91.
74.Bost, F., et al., Energy disruptors: rising stars in anticancer therapy? Oncogenesis, 2016. 5: p. e188.
75.Fogarty, S. and D.G. Hardie, Development of protein kinase activators: AMPK as a target in metabolic disorders and cancer. Biochim Biophys Acta, 2010. 1804(3): p. 581-91.
76.Clem, B.F., et al., Clinical development of cancer therapeutics that target metabolism. Qjm, 2016. 109(6): p. 367-72.
77.Vander Heiden, M.G., L.C. Cantley, and C.B. Thompson, Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science, 2009. 324(5930): p. 1029-33.
78.Zhang, W., et al., Targeting tumor metabolism for cancer treatment: is pyruvate dehydrogenase kinases (PDKs) a viable anticancer target? Int J Biol Sci, 2015. 11(12): p. 1390-400.
79.Saikali, Z., et al., Role of IGF-1/IGF-1R in regulation of invasion in DU145 prostate cancer cells. Cancer Cell Int, 2008. 8: p. 10.
80.Ippolito, L., et al., Metabolic shift toward oxidative phosphorylation in docetaxel resistant prostate cancer cells. Oncotarget, 2016. 7(38): p. 61890-61904.
81.Yoshida, G.J., Metabolic reprogramming: the emerging concept and associated therapeutic strategies. J Exp Clin Cancer Res, 2015. 34: p. 111.
82.Raimundo, N., B.E. Baysal, and G.S. Shadel, Revisiting the TCA cycle: signaling to tumor formation. Trends Mol Med, 2011. 17(11): p. 641-9.
83.Chaube, B., et al., AMPK maintains energy homeostasis and survival in cancer cells via regulating p38/PGC-1alpha-mediated mitochondrial biogenesis. Cell Death Discov, 2015. 1: p. 15063.
84.Davies, S.P., A.T. Sim, and D.G. Hardie, Location and function of three sites phosphorylated on rat acetyl-CoA carboxylase by the AMP-activated protein kinase. Eur J Biochem, 1990. 187(1): p. 183-90.
85.Lau, A.W., et al., SIRT1 phosphorylation by AMP-activated protein kinase regulates p53 acetylation. Am J Cancer Res, 2014. 4(3): p. 245-55.
86.Sancho, P., et al., MYC/PGC-1alpha balance determines the metabolic phenotype and plasticity of pancreatic cancer stem cells. Cell Metab, 2015. 22(4): p. 590-605.
87.Villar, V.H., et al., Glutaminolysis and autophagy in cancer. Autophagy, 2015. 11(8): p. 1198-208.
88.Li, X., et al., AMPK-mediated energy homeostasis and associated metabolic effects on cancer cell response and resistance to cetuximab. Oncotarget, 2015. 6(13): p. 11507-18.
89.Tennakoon, J.B., et al., Androgens regulate prostate cancer cell growth via an AMPK-PGC-1alpha-mediated metabolic switch. Oncogene, 2014. 33(45): p. 5251-61.
90.Kumar, A., U.K. Singh, and A. Chaudhary, Targeting autophagy to overcome drug resistance in cancer therapy. Future Med Chem, 2015. 7(12): p. 1535-42.
91.Weerasekara, V.K., et al., Metabolic-stress-induced rearrangement of the 14-3-3zeta interactome promotes autophagy via a ULK1- and AMPK-regulated 14-3-3zeta interaction with phosphorylated Atg9. Mol Cell Biol, 2014. 34(24): p. 4379-88.
92.Hu, Y.L., et al., Tumor cell autophagy as an adaptive response mediating resistance to treatments such as antiangiogenic therapy. Cancer Res, 2012. 72(17): p. 4294-9.
93.Jeon, S.M., N.S. Chandel, and N. Hay, AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature, 2012. 485(7400): p. 661-5.
94.Virtue, S. and A. Vidal-Puig, Nothing iffy about HIF in the hypothalamus. PLoS Biol, 2011. 9(7): p. e1001116.
95.Memmott, R.M. and P.A. Dennis, Akt-dependent and -independent mechanisms of mTOR regulation in cancer. Cell Signal, 2009. 21(5): p. 656-64.
96.O''Hagan, K.A., et al., PGC-1alpha is coupled to HIF-1alpha-dependent gene expression by increasing mitochondrial oxygen consumption in skeletal muscle cells. Proc Natl Acad Sci U S A, 2009. 106(7): p. 2188-93.
97.Yu, L., et al., Modeling the genetic regulation of cancer metabolism: interplay between glycolysis and oxidative phosphorylation. Cancer Res, 2017. 77(7): p. 1564-1574.
98.Zadra, G., J.L. Batista, and M. Loda, Dissecting the dual role of AMPK in cancer: from experimental to human studies. Mol Cancer Res, 2015. 13(7): p. 1059-72.
99.Liu, X., et al., Discrete mechanisms of mTOR and cell cycle regulation by AMPK agonists independent of AMPK. Proc Natl Acad Sci U S A, 2014. 111(4): p. E435-44.
100.Ben Sahra, I., et al., Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res, 2011. 71(13): p. 4366-72.
101.Ben Sahra, I., et al., The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene, 2008. 27(25): p. 3576-86.
102.Foretz, M., et al., Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest, 2010. 120(7): p. 2355-69.
103.Wright, C., et al., Anti-tumorigenic potential of a novel orlistat-AICAR combination in prostate cancer cells. J Cell Biochem, 2017.
104.Jeon, J.Y., et al., The bifunctional autophagic flux by 2-deoxyglucose to control survival or growth of prostate cancer cells. BMC Cancer, 2015. 15: p. 623.
105.Raez, L.E., et al., A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol, 2013. 71(2): p. 523-30.
106.Stein, M., et al., Targeting tumor metabolism with 2-deoxyglucose in patients with castrate-resistant prostate cancer and advanced malignancies. Prostate, 2010. 70(13): p. 1388-94.
107.Van Den Neste, E., et al., Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II study. Cancer Chemother Pharmacol, 2013. 71(3): p. 581-91.
108.Michaelson, M.D., et al., Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer. J Clin Oncol, 2014. 32(2): p. 76-82.
109.Laderoute, K.R., et al., SU11248 (sunitinib) directly inhibits the activity of mammalian 5''-AMP-activated protein kinase (AMPK). Cancer Biol Ther, 2010. 10(1): p. 68-76.
|